Pellerino, A.; Soffietti, R.; Bruno, F.; Manna, R.; Muscolino, E.; Botta, P.; Palmiero, R.; Rudà , R.
Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. Cancers 2022, 14, 1192.
https://doi.org/10.3390/cancers14051192
AMA Style
Pellerino A, Soffietti R, Bruno F, Manna R, Muscolino E, Botta P, Palmiero R, Rudà R.
Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. Cancers. 2022; 14(5):1192.
https://doi.org/10.3390/cancers14051192
Chicago/Turabian Style
Pellerino, Alessia, Riccardo Soffietti, Francesco Bruno, Roberta Manna, Erminia Muscolino, Pierangela Botta, Rosa Palmiero, and Roberta Rudà .
2022. "Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program" Cancers 14, no. 5: 1192.
https://doi.org/10.3390/cancers14051192
APA Style
Pellerino, A., Soffietti, R., Bruno, F., Manna, R., Muscolino, E., Botta, P., Palmiero, R., & Rudà , R.
(2022). Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. Cancers, 14(5), 1192.
https://doi.org/10.3390/cancers14051192